Pharmacogenetics and individualized therapy in children: Immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs

Pharmacogenomics

Volumn 12, Issue 6, 2011, Pages 827-843

  Elie, Valery ^a   De Beaumais, Tiphaine ^a   Fakhoury, May ^a   Jacqz Aigrain, Evelyne ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

adverse drug reactions; antidepressants; immunosuppressants; mercaptopurine; metabolomics; nutrition; ontogeny; pediatrics; pharmacogenetics

Indexed keywords

ABACAVIR; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ATAZANAVIR; CARBAMAZEPINE; CODEINE; CYCLOSPORIN; DEXTROMETHORPHAN; EFAVIRENZ; FLUCLOXACILLIN; IBUPROFEN; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; MICRORNA; MORPHINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; NORTRIPTYLINE; PANTOPRAZOLE; TACROLIMUS; TRAMADOL; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; BLOOD TOXICITY; BONE MARROW TOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; DIARRHEA; DISEASE PREDISPOSITION; DNA METHYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TRANSPORT; EPIGENETICS; GENE EXPRESSION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEPATOMEGALY; HISTONE MODIFICATION; HUMAN; HYPERBILIRUBINEMIA; KIDNEY TRANSPLANTATION; LACTIC ACIDOSIS; LEUKOPENIA; LIVER TOXICITY; METABOLOMICS; NEOPLASM; NUTRITION; PERSONALIZED MEDICINE; PHARMACOGENETICS; REVIEW; RNA INTERFERENCE; SEIZURE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 79959450420     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.19     Document Type: Review

References (169)

1. Johnson AD, Wang D, Sadee W: Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. Pharmacol. Ther. 106, 19-38 (2005). (Pubitemid 40392460)
2. Ingelman-Sundberg M, Sim SC: Intronic polymorphisms of cytochromes P450. Hum Genomics. 4, 402-405 (2010).
3. Johnson AD, Papp Y, Pinsonneault JK et al.: Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression inbalance in human target tissues. Pharmacogenet. Genomics. 18, 781-791 (2008).
4. Cheung VG, Nayak RR, Wang IX et al.: Polymorphic cis and trans-regulation of human gene expression. PLoS Bio. 8(9), pii: e1000480 (2010).
5. Yan H, Yuan W, Velculescu V, Vogelstein B, Kinzler KW: Allelic variation in human gene expression. Science 297, 1143 (2002). (Pubitemid 36193340)
6. Bray NJ, Buckland PR, Owen MJ, O'Donavan MC: Cis-acting variation in the expression of a high proportion of genes in human brain. Hum. Genet. 113, 149-153 (2003). (Pubitemid 36873754)
7. Lo HS, Wang Z, Hu Y et al.: Allelic variation in gene expression is common in the human genome. Genome Res. 13, 1855-1862 (2003). (Pubitemid 36987191)
8. Rushmore TH, Kong AN: Pharmacogenomics, regulation and signaling pathways of phase 1 and 2 drug metabolizing enzymes. Curr. Drug Metab. 3, 481-490 (2002). (Pubitemid 34987481)
9. Akiyama TE, Gonzalez FJ: Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors. Biochem. Biophys. Acta. 1619, 223-234 (2003). (Pubitemid 36163418)
10. Chen K, Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat. Rev. Genet. 8, 93-103 (2007). (Pubitemid 46122839)
11. Mazumder B, Seshadri V, Fox PL: Translational control by the 3́UTR: the ends specify the matter. Trends Biochem. Sci. 28, 91-98 (2003). (Pubitemid 36165138)
12. Selbach M, Schwanhäusser B, Thierfelder N: Widespread changes in protein synthesis induced by microRNAs. Nature 455, 58-635 (2008).
13. Bertino J, Banerjee D, Mishra PJ: Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Pharmacogenomics 8, 1625-1627 (2007).
14. Mishra PJ, Bertino JR: MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 10, 399-416 (2009).
15. Tokizane T Shijna H, Igawa M et al.: Cytochrome P4501B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin. Cancer Res. 11, 5793-5801 (2005). (Pubitemid 41170305)
16. Moschos SA: The role of miRNA in diagnostics. Int. Drug Discov. 5, 10-17 (2010).
17. Wong AHC, Gottesman II, Petronis A: Phenotypic differences in genetically identical organisms: the epigenetic perspective. Hum. Mol. Genet. 14, R11-R18 (2005). (Pubitemid 40542615)
18. Gosden RG, Feinberg AP: Genetics and epigenetics - nature's pen-and-pencil set. N. Engl. J. Med. 356, 731-733 (2007).
19. Reik W: Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447, 425-432 (2007). (Pubitemid 46816749)
20. Adcock IM, Ito K: Glucocorticoid pathways in chronic obstructive pulmonary disease therapy. Proc. Am. Thorac. Soc. 2, 313-319 discussion 340-341 (2005). (Pubitemid 41566942)
21. Ingrosso D, Cimmino A, Perna AF et al.: Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 361, 1693-1699 (2003). (Pubitemid 36577442)
22. Wilson AG: Epigenetic regulation of gene expression in the inflammatory response and relevance to common diseases. J. Periodontol. 79, 1514-1519 (2008).
23. Grewal SIS, Mozad D: Heterochromatin and epigenetic control of gene expression. Science 301, 798-801 (2003).
24. Berger SL: The complex language of chromatin regulation during transcription. Nature 447, 407-412 (2007). (Pubitemid 46816746)
25. Adcock IM, Ford P, Ito K, Barnes PJ: Epigenetics and airways disease. Respir. Res 7, 21 (2006).
26. Tufarelli C, Stanley JAS, Garrick D et al.: Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat. Genet. 34, 157-165 (2003). (Pubitemid 36666926)
27. Li E: Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 3, 662-673 (2002). (Pubitemid 34984255)
28. Cedar H, Bergman Y: Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 10, 295-304 (2009).
29. Fraga MF, Ballestar E, Paz MF et al.: Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA 102, 10604-10609 (2005). (Pubitemid 41061601)
30. Reik W, Dean W, Walter J: Epigenetic reprogramming in mammalian development. Science 293, 1089-1093 (2001). (Pubitemid 32758081)
31. Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature 447, 433-440 (2007). (Pubitemid 46816750)
32. Kucharski R, Maleszka J, Foret S, Maleszka R: Nutritional control of reproductive status in honeybees via DNA methylation. Science 319, 1827-1830 (2008). (Pubitemid 351451590)
33. Morgan HD, Sutherland HG, Martin DI, Whitelaw E: Epigenetic inheritance at the agouti locus in the mouse. Nat. Genet. 23, 314-318 (1999). (Pubitemid 29526429)
34. Delage B, Dashwood RH: Dietary manipulation of histone structure and function. Ann. Rev. Nutr. 28, 347-366 (2008).
35. Blake MJ, Abdel-Rahman SM, Pearce RE, Leeder JS, Kearns GL: Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr. Res. 60, 717-723 (2006). (Pubitemid 44789515)
36. Kaati G, Bygren LO, Edvinsson S: Cardiovascular and diabetes mortality determined by nutrition during parents' and grandparents' slow growth period. Eur. J. Hum. Genet. 10, 682-688 (2002). (Pubitemid 35460575)
37. Weaver ICG, Cervoni N, Champagne FA et al.: Epigenetic programming by maternal behavior. Nat. Neurosci. 7, 847-854 (2004). (Pubitemid 38989508)
38. Szyf M, Weaver ICG, Champagne FA, Diorio J, Meaney MJ: Maternal programming of steroid receptor expression and phenotype through DNA methylation in the rat. Front. Neuroendocrinol. 26, 139-162 (2005). (Pubitemid 41772652)
39. Barnes PJ, Adcock IM: How do corticosteroids work in asthma? Ann. Intern. Med. 139, 359-370 (2003). (Pubitemid 38124591)
40. Anttila S, Hakkola J, Tuominen P et al.: Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking. Cancer Res. 63, 8623-8628 (2003). (Pubitemid 38064036)
41. Grossniklaus D: Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: test category: pharmacogenomic (treatment). PLoS Curr. 2, pii: RRN1155 (2010).
42. Tan GM, Wu E, Lam YY, Yan BP: Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 11, S439-S448 (2010).
43. Schroth W, Goetz MP, Hamann U et al.: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009).
44. Simon T, Verstuyft C, Mary-Krause M et al.: Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
45. Lennard L, Welch JC, Lilleyman JS: Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br. J. Clin. Pharmacol. 44, 455-461 (1997). (Pubitemid 27485476)
46. Stanulla M, Schaeffeler E, Flohr T et al.: Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 23, 1485-1489 (2005). (Pubitemid 40393293)
47. Gazouli M, Pachoula I, Panayotou I et al.: Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients. J. Clin. Pharmacol. Ther. 35, 93-97 (2010).
48. Török HP, Göke B, Konrad A: Pharmacogenetics of Crohn's disease. Pharmacogenomics 9, 881-893 (2008).
49. Maemondo M, Inoue A, Kobayashi K et al.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
50. Mok TS, Wu YL, Thongprasert S et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
51. Lièvre A, Bachet JB, Le Corre D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3392-3395 (2006).
52. Le XF, Pruefer F, Bast RC Jr: HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signalling pathways. Cell Cycle. 4, 87-95 (2005). (Pubitemid 41038933)
53. Rifell AK, Schuenemann E, Vyhlidal CA: Regulation of the CYP3A4 promoters by members of the nuclear factor I transcription factor family. Mol. Pharmacol. 76, 1104-1114 (2009).
54. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE: Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167 (2003). (Pubitemid 37122329)
55. Leeder JS, Kearns GL, Spielberg SP, van den Anker J: Understanding the relative roles of pharmacogenetics and ontogeny in paediatric drug development and regulatory science. J. Clin. Pharmacol. 50(12), 1377-1387 (2010).
56. Hines RN: The ontogeny of drug metabolism enzymes and implications in adverse drug reactions. Pharmacol. Ther. 118, 250-267 (2008).
57. Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. S33, 245-254 (2003). (Pubitemid 36278835)
58. Davidsen ML, Dalhoff K, Schmiegelow K: Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 30, 831-849 (2003).
59. Pui CH, Pei D, Sandlund JT et al.: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730-2741 (2009).
60. McLeod HL, Krynetski EY, Relling MV, Evans WE: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukaemia. Leukemia 14, 567-572 (2000). (Pubitemid 30195445)
61. Stocco G, Crews KR, Evans WE: Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert. Opin. Drug Saf. 9, 23-37 (2010).
62. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenetic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651-662 (1980). (Pubitemid 10061685)
63. Arenas M, Duley J, Sumi S, Sanderson J, Marinaki A: The ITPA c.94C>A and IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene. Biochim. Biophys. Acta 772, 96-102 (2007). (Pubitemid 44960729)
64. Sumi S, Marinaki AM, Arenas M et al.: Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet. 111, 360-367 (2002). (Pubitemid 36075062)
65. Lennard L, Lilleyman JS, van Loon J, Weinshilboum RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336, 225-229 (1990). (Pubitemid 20229068)
66. Zukic B, Radmilovic M, Stojilikovic M et al.: Functional analysis of the role of the TPMT gene promoter VNTR polymorphism in TPMT gene transcription. Pharmacogenomics 11, 547-557 (2010).
67. Hawwa AF, Collier PS, Millership JS et al.: Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br. J. Clin. Pharmacol. 66, 826-837 (2008).
68. Krajinovic M, Moghrabi A: Pharmacogenetics of methotrexate. Pharmacogenomics 5, 819-834 (2004). (Pubitemid 39386751)
69. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Barnerjee D, Bertino JR: A miR-24 microRNA binding site polymorphism in dihydrofolate gene reductase gene leads to methotrexate resistance. Proc. Natl Acad. Sci. USA 104, 13513-13518 (2007). (Pubitemid 47293976)
70. Adam de Beaumais T, Fakhoury M, Medard Y et al.: Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br. J. Clin. Pharmacol. 71(4), 575-584 (2010).
71. Naoe T, Takeyama K, Yokozawa T et al.: Analysis of genetic polymorphisms in NQO1, GST-M1, GST-T1 and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin. Cancer Res. 6, 4091-4095 (2000).
72. Wojnowski L, Hustert E, Klein K et al.: Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer. Inst. 94, 630-631 (2002).
73. Lin YS, Dowling AL, Quigley SD et al.: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62, 162-172 (2002). (Pubitemid 34680528)
74. Thervet E, Anglicheau D, Legendre C, Beaume P: Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther. Drug. Monit. 30, 143-150 (2008). (Pubitemid 351521640)
75. Anglicheau D, Legendre C, Beaune P, Thervet E: Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 8, 835-849 (2007). (Pubitemid 47288980)
76. Haushofer A: Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. Pharmacogenomics 6, 163-168 (2005). (Pubitemid 40613182)
77. De Wildt SN, Kearns GL, Leeder JS, van den Anker JN: Cytochrome 450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37, 485-505 (1999). (Pubitemid 30032252)
78. Pauli-Magnus C, Kroetz DL: Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharma. Res. 21, 904-913 (2004). (Pubitemid 38870137)
79. Kim RB: MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12, 425-427 (2002). (Pubitemid 34913525)
80. Tang K, Ngoi SM, Gwee PC et al.: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12, 437-450 (2002). (Pubitemid 34913526)
81. Giraud C, Decleves X Perrot JY, Manceau S et al.: High levels of P-glycoprotein activity in human lymphocytes in the first 6 months of life. Clin. Pharmacol. Ther. 83, 289-295 (2009).
82. Sharom FJ: ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9, 105-127 (2009). (Pubitemid 351560534)
83. Anglicheau D, Thervet E, Etienne I et al.: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther. 75, 422-433 (2004). (Pubitemid 38534563)
84. Fanta S, Niemi M, Jönsson S et al.: Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet. Genomics 18, 77-90 (2008).
85. Hesselink DA, van Schaik RH, Nauta J, van Gelder T: A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of ciclosporine. Pharmacogenomics 9, 783-789 (2009).
86. Thervet E, Loriot MA, Barbier S et al.: Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87, 721-726 (2010).
87. Zhao W, Elie V, Roussey G et al.: Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin. Pharmacol. Ther. 86, 609-618 (2009).
88. Miners JO, McKinnon RA, Mackenzie PI: Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181-182, 453-456 (2001).
89. Argikar UA, Iwuchukwu OF, Nagar S: Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms. Exp. Opin. Drug Metab. Toxicol. 4, 879-894 (2004).
90. De Wildt SN, Kearns GL, Leeder JS, van den Anker JN: Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin. Pharmacokinet. 36, 439-452 (1999). (Pubitemid 29317491)
91. Girard H, Court MH, Bernard O et al.: Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14, 501-515 (2004). (Pubitemid 39100002)
92. Bernard O, Guillemette C: The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Disp. 32, 775-778 (2004). (Pubitemid 38955603)
93. Bhasker CR, McKinnon W, Stone A et al.: Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10, 679-685 (2000).
94. Sawyer MB, Innocenti F, Das S et al.: A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin. Pharmacol. Ther. 73, 566-574 (2003). (Pubitemid 37249128)
95. Zhao W, Fakhoury M, Deschênes G et al.: Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal transplant patients. J. Clin. Pharmacol. 50, 1280-1291 (2010).
96. van Schaik RH, van Agteren M, de Fijter JW et al.: UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/ tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther. 86, 319-327 (2009).
97. Grenda R, Prokurat S, Ciechanowicz A, Piatosa B, Kalici?ski P: Evaluation of the genetic background of standard-immunosuppressant-related toxicity in a cohort of 200 paediatric renal allograft recipients - a retrospective study. Ann. Transplant. 14, 18-24 (2009).
98. Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P4502D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13 (2005). (Pubitemid 40220611)
99. Yu A, Haining RL: Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a probe drug for both CYP2D6 and CYP3A4 activities? Drug Metab. Dispos. 29, 1514-1520 (2001). (Pubitemid 33000701)
100. Blake MJ, Gaedigk A, Pearce RE et al.: Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin. Pharmacol. Ther. 81, 510-516 (2007). (Pubitemid 46452306)
101. Allegaert K, Rochette A, Veyckemans F: Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Paediatr. Anesth. 21(3), 266-273 (2010).
102. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368(9536), 704 (2006). (Pubitemid 44223697)
103. Madadi P, Ross CJ, Hayden MR et al.: Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin. Pharmacol. Ther. 85, 31-35 (2009).
104. Tremlett M, Anderson BJ, Wolf A: Pro-con debate: is codeine a drug that still has a useful role in pediatric practice? Paediatr. Anaesth. 20, 183-194 (2010).
105. Hammer W, Sjoqvist F: Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like coumpounds. Life Sci. 6, 1895-1903 (1969).
106. Bertilsson L, Aberg-Wistedlt A, Gutafsson LL, Nordin C: Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther. Drug Monit. 7, 478-480 (1985). (Pubitemid 16198538)
107. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: part 1: Clin. Pharmacokinet. 48, 689-723 (2009).
108. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II: Clin. Pharmacokinet. 48, 761-804 (2009).
109. Zackrisson AL, Lindblom B, Ahlner J: High frequency of occurrence of CYP2D6 gene duplication/multiplication indicating ultrarapid metabolism among suicide cases. Clin. Pharmacol. Ther. 88, 354-359 (2010).
110. Bertilsson L: CYP2D6, serotonin and suicide - a relationship? Clin. Pharmacol. Ther. 88, 304-305 (2010).
111. Seeringer A, Kirchheiner J: Pharmacogenetics - guided dose modifications of antidepressants. Clin. Lab. Med. 60, 238-255 (2008).
112. Dai D, Zeldin DC, Blaisdell JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11, 597-607 (2001). (Pubitemid 32953585)
113. Agundez JA, Garcia-Martin E, Martinez C: Genetically-based impairment in CYP2C8 and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine. Exp. Opin. Drug Metab. Toxicol. 5, 607-620 (2009).
114. Totah RA, Rettie AE: Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther. 77, 341-352 (2005). (Pubitemid 40719263)
115. Martinez C, Garcia-Martin E, Blanco G, Gamito FJ, Ladero JM, Agundez JA: The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)- ibuprofen enantiomer in healthy subjects. Br. J. Clin. Pharmacol. 59, 62-69 (2005).
116. Pedersen RS, Brasch-Andersen C, Sim SC et al.: Linkage disequilibrium between the CYP2C19*17 allele and wild type CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur. J. Clin. Pharmacol. 66(12), 1199-1205 (2010).
117. Rodrigues AD: Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab. Dispos. 33, 1567-1575 (2005). (Pubitemid 41541940)
118. Daily EB, Aquilante C: Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 10, 1489-1510 (2009).
119. Leemann TD, Transon C, Bonnabry P, Dayer P: A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp. Clin. Res. 9, 189-195 (1993). (Pubitemid 24029190)
120. Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA: Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther. 76, 119-127 (2004). (Pubitemid 39013402)
121. Yasar U, Lundgren S, Eliasson E et al.: Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun. 299, 25-28 (2002). (Pubitemid 35366030)
122. Naraharisetti SB, Lin YS, Rieder MJ et al.: Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab. Dispos. 38, 889-893 (2010).
123. Wang G, Lei HP, Li Z et al.: The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur. J. Clin. Pharmacol. 65, 281-285 (2009).
124. Lithalien C, Theoret Y, Faure C: Pharmacokinetics of proton pump inhibitors in children. Clin. Pharmacokinet. 44, 441-466 (2005). (Pubitemid 40733732)
125. Klotz U: Clinical impact of CYP2C19 on the action of proton pump inhibtors: a review of a special problem. Int. J. Clin. Pharmacol. Ther. 39, 295-309 (2006).
126. Kearns GL, Leeders JS, Gaedigk A: Impact of the CYPC2C*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab. Dispos. 38, 894-897 (2010).
127. Chung WH, Hung SI, Hong HS et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
128. Sim SC, Risinger C, Dahl ML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103-113 (2006). (Pubitemid 43069582)
129. Tozzi V: Pharmacogenetics of antiretrovirals. Antiviral Res. 85, 190-200 (2010).
130. Daly AK, Donaldson PT, Bhatnagar P et al.: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816-819 (2009).
131. Becquemont L, Alfirevic A, Amstutz U et al.: Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 12(1), 113-124 (2010).
132. Ingelman-Sundberg M, Sim SC: Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem. Biophys. Res. Commun. 21, 396, 90-94 (2010).
133. Gallagher WM, Tweats D, Koenig J: Omic profiling for drug safety assessments: current trends and public-private partnerships. Drug Discov. Today 14, 337-342 (2009).
134. Amar PJ, Schiff ER: Acetaminophen safety and hepatotoxicity: where do we go from here? Expert Opin. Drug Saf. 6, 341-355 (2007). (Pubitemid 351308163)
135. Zaher H, Buters JT, Ward JM et al.: Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol. Appl. Pharm. 152, 193-199 (1998). (Pubitemid 28498688)
136. Neafsey P, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B: Genetic polymorphism in CYP2E1: population distribution of CYP2E1 activity. J. Toxicol. Environ. Health B Crit. Rev. 12, 362-388 (2009).
137. McCarver DG, Byun R, Hines RN, Hichme M, Wegenek W: A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increase chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. J. Biol. Chem. 152, 276-281 (2000). (Pubitemid 28498696)
138. Shadley JD, Divakaran K, Munson K, Hines RN, Douglas K, McCarver DG: Identification and functional analysis of a novel human CYP2E1 far upstream enhancer. Mol. Pharmacol. 71, 1630-1639 (2007). (Pubitemid 47010916)
139. Yamamoto T, Tomizawa K, Fujikawa M, Sato Y, Yamada H, Horii I: Evaluation of human hepatocyte chimeric mice as a model for toxicological evaluation using panomic approaches - effect of acetaminophen on the expression of proteins and endogenous metabolites in liver, plasma and urine. J. Toxicol. Sci. 32, 205-215 (2007). (Pubitemid 47403191)
140. Welch KD, Reilly TP, Bourdi M et al.: Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice. Chem. Res. Toxicol. 19, 223-233 (2006).
141. Clayton TA, Lindon JC, Cloarec O et al.: Pharmaco-metabolomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).
142. O'Connell TM, Watkins PB: The application of metabolomics to predict drug-induced liver injury. Clin. Pharmacol. Ther. 88, 394-399 (2010).
143. Fannin RD, Russo M, O'Connell TM et al.: Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology 51, 227-236 (2010).
144. Gu H, Pan Z, Xi B et al.: 1H NMR metabolomic study of age profiling in children. NMR Biomed. 22, 826-833 (2009).
145. Anderson G: Endotyping asthma: new insights into key pathogenic mechanisms in a complex heterogeneous disease. Lancet 372, 1107-1119 (2008).
146. Beger R, Holland R, Sun J et al.: Metabolomics of acute kidney injury in children after cardiac surgery. Paed. Nephrol. 23, 977-984 (2008).
147. Wolak JE, Esther CR, O'Connell TM: Meabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients. Biomarkers 14, 55-60 (2009).
148. Sjöqvist F, Bertilsson L: Clinical pharmacology of antidepressant drugs: pharmacogenetics. Adv. Biochem. Psychopharmacol. 39, 359-372 (1984).
149. Coffman BL, King CD, Rios GR, Tephly TR: The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos. 26, 73-77 (1998). (Pubitemid 28071328)
150. Knibbe CA, Krekels EH, van den Anker JN et al.: Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin. Pharmacokinet. 48, 371-385 (2009).
151. Laverdière C, Chiasson S, Costea I, Moghrabi A, Krajinovic M: Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100, 3832-3834 (2002). (Pubitemid 35303961)
152. Gregers J, Christensen IJ, Dalhoff K et al.: The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 115, 4671-4677 (2010).
153. Cheng Q, Wu B, Kager L et al.: A substrate specific functional polymorphism of human g-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics 14, 557-567 (2004). (Pubitemid 39100007)
154. Garcia-Bournissen F, Moghrabi A, Krajinovic M: Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of g glutamyl hydrolase (GGH) gene. Leuk. Res. 31, 1023-1025 (2007). (Pubitemid 46856715)
155. Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T: High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin. Pharmacol. Ther. 280, 468-476 (2006). (Pubitemid 44737489)
156. Ansari M, Sauty G, Labuda M et al.: Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 114, 1383-1386 (2009).
157. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM: Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 119, 985-989 (1991).
158. Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I: Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia 23, 971-974 (2009).
159. Hawwa AF, Millership JS, Collier PS et al.: Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br. J. Clin. Pharmacol. 66, 517-528 (2008).
160. Lennard L, van Loon JA, Lilleyman JS, Weinshilboum RM: Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin. Pharmacol. Ther. 41, 18-25 (1987). (Pubitemid 17008125)
161. Relling MV, Hancock ML, Rivera GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91, 2001-2008 (1997).
162. Fanta S, Jönsson S, Backman JT, Karlsson MO, Hoppu K: Developmental pharmacokinetics of ciclosporin - a population pharmacokinetic study in paediatric renal transplant candidates. Br. J. Clin. Pharmacol. 64, 772-778 (2007).
163. Mino Y, Naito T, Otsuka A et al.: Cyclosporine concentration-dependent increase in concentration ratio of mycophenolic acid acyl and phenol
164. Zheng H, Zeevi A, Schuetz E et al.: Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. 44, 135-140 (2004). (Pubitemid 38114311)
165. Tada H, Tsuchiya N, Satoh S et al.: Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant. Proc. 37, 1730-1732 (2005). (Pubitemid 40790812)
166. Haufroid V, Wallemacq P, VanKerckhove V et al.: CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am. J. Transplant. 6, 2706-2713 (2006). (Pubitemid 44571691)
167. Zheng H, Webber S, Zeevi A et al.: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. 3, 477-483 (2003). (Pubitemid 36560101)
168. Fukudo M, Yano I, Masuda S et al.: Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin. Pharmacol. Ther. 331-345 (2006). (Pubitemid 44479749)
169. Masuda S, Uemoto S, Goto M, Fujimoto Y, Tanaka K, Inui K: Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin. Pharmacol. Ther. 75, 352-361 (2004). (Pubitemid 38471560)